Geneuro SA is a Switzerland-based clinical stage pharmaceutical company that develops treatments for autoimmune diseases, including multiple sclerosis (MS) and other diseases associated with human endogenous retroviruses (HERV). The Company's main product, GNbAC1, is a humanized monoclonal antibody that is in clinical development phase IIb. GNbAC1 neutralizes the MSRV-Env protein rather than targeting the patient's immune system, and slows down or even halts the progression of multiple sclerosis. The Company's main shareholders are Eclosion2, a launching platform for new companies in the life sciences field, bioMerieux SA, which specializes in vitro diagnostics for medical and industrial applications, Institut Merieux, a private equity company, and Servier, an independent French pharmaceutical company.

Type
Public
HQ
Plan Les Ouates, CH
Size (employees)
21 (est)
Website
geneuro.ch
GeNeuro is headquartered in Plan-les-Ouates, CH

GeNeuro Office Locations

GeNeuro has an office in Plan-les-Ouates
Plan Les Ouates, CH (HQ)
18 Chemin Des Aulx

GeNeuro Data and Metrics

GeNeuro Financial Metrics

Numbers are in €, EUR

Market capitalization (23-May-2017)

145.1 m

Closing share price (23-May-2017)

10
GeNeuro's current market capitalization is €145.1 m.

GeNeuro Market Value History

GeNeuro Company Life and Culture

You may also be interested in